Referencias

1. Al Sarakbi W, Salhab M, Mokbel K. Does mammary ductoscopy have a role in clinical practice? Int Semin Surg Oncol. 2006 Jun 30;3:16. | CrossRef | PubMed
2. Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, et al. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res. 2007 Aug 15;13(16):4943-8. | CrossRef | PubMed
3. Begum P, Richardson CE, Carmichael AR. Obesity in post menopausal women with a family history of breast cancer: prevalence and risk awareness. Int Semin Surg Oncol. 2009 Jan 8;6:1. | CrossRef | PubMed
4. Berg WA. Tailored supplemental screening for breast cancer: what now and what next? AJR Am J Roentgenol. 2009 Feb;192(2):390-9. | CrossRef | PubMed
5. Bethwaite P, Smith N, Delahunt B, Kenwright D. Reproducibility of new classification schemes for the pathology of ductal carcinoma in situ of the breast. J Clin Pathol. 1998 Jun;51(6):450-4. | CrossRef | PubMed
6. Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001 Apr 15;19(8):2263-71. | PubMed
7. Bondy ML, Newman LA. Assessing breast cancer risk: evolution of the Gail Model. J Natl Cancer Inst. 2006 Sep 6;98(17):1172-3. | CrossRef | PubMed
8. Brekelmans CT, Seynaeve C, Bartels CC, Tilanus-Linthorst MM, Meijers-Heijboer EJ, Crepin CM, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 2001 Feb 15;19(4):924-30. | PubMed
9. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006 May;19(5):617-21. | CrossRef | PubMed
10. Campbell KL, McTiernan A. Exercise and biomarkers for cancer prevention studies. J Nutr. 2007 Jan;137(1 Suppl):161S-169S. | PubMed
11. Collins LC, Schnitt SJ. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol. 2005 May;18(5):615-20. | CrossRef | PubMed
12. Crispo A, D'Aiuto G, De Marco M, Rinaldo M, Grimaldi M, Capasso I, et al. Gail model risk factors: impact of adding an extended family history for breast cancer. Breast J. 2008 May-Jun;14(3):221-7. Epub 2008 Mar 26. | CrossRef | PubMed
13. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007 Feb 21;99(4):272-82. | CrossRef | PubMed
14. Dabbs DJ, Johnson R. The optimal number of sentinel lymph nodes for focused pathologic examination. Breast J. 2004 May-Jun;10(3):186-9. | CrossRef | PubMed
15. De Tavassoli FA, Devilee P. World Health Organization Classification of Tumors. Pathology and Genetics: Tumors of the reast and Female Genital Organs. Lyon: IARC Press, 2001.
16. Decarli A, Calza S, Masala G, Specchia C, Palli D, Gail MH. Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort. J Natl Cancer Inst. 2006 Dec 6;98(23):1686-93. | CrossRef | PubMed
17. Dershaw DD. Mammographic screening of the high-risk woman. Am J Surg. 2000 Oct;180(4):288-9. | CrossRef | PubMed
18. Dershaw DD. Does LCIS or ALH without other high-risk lesions diagnosed on core biopsy require surgical excision? Breast J. 2003 Jan-Feb;9(1):1-3. | CrossRef | PubMed
19. Dershaw DD, Yahalom J, Petrek JA. Breast carcinoma in women previously treated for Hodgkin disease: mammographic evaluation. Radiology. 1992 Aug;184(2):421-3. | PubMed
20. Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, et al. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat. 2008 Jun;109(3):405-16. Epub 2007 Aug 9. | CrossRef | PubMed
21. Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 2005;7(1):R93-100. Epub 2004 Nov 19. | CrossRef | PubMed
22. Elsheikh TM, Silverman JF. Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature. Am J Surg Pathol. 2005 Apr;29(4):534-43. | CrossRef | PubMed
23. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62. | CrossRef | PubMed
24. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005 Apr 10;114(3):448-54. | CrossRef | PubMed
25. Gilleard O, Goodman A, Cooper M, Davies M, Dunn J. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J Surg Oncol. 2008 Jun 18;6:61. | CrossRef | PubMed
26. Gómez F. Evaluación cuantitativa del riesgo de cáncer de mama. Rev Rev. Med. Clin. Condes - 2006; 17(4): 149 – 63. | Link
27. Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8(3):R25. Epub 2006 May 31. | CrossRef | PubMed
28. Harris EE, Solin LJ. The Diagnosis and Treatment of Ductal Carcinoma In Situ of the Breast. Breast J. 2000 Mar;6(2):78-95. | CrossRef | PubMed
29. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007 Nov 20;25(33):5287-312. Epub 2007 Oct 22. | CrossRef | PubMed
30. Honrado E, Benítez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol. 2005 Oct;18(10):1305-20. | CrossRef | PubMed
31. Jacobi CE, de Bock GH, Siegerink B, van Asperen CJ. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat. 2009 May;115(2):381-90. Epub 2008 May 30. | CrossRef | PubMed
32. Jacobs TW. Recently Recognized Variants of Lobular Carcinoma In Situ (LCIS) With an Emphasis on Management of LCIS on Core Needle Biopsy. Pathology Case Review. 2003; 8(5): 211-19.
33. Jirström K, Ringberg A, Fernö M, Anagnostaki L, Landberg G. Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. Br J Cancer. 2003 Nov 17;89(10):1920-6. | CrossRef | PubMed
34. Kaas R, Verhoef S, Wesseling J, Rookus MA, Oldenburg HS, Peeters MJ, et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg. 2010 Mar;251(3):488-92. | CrossRef | PubMed
35. Karabakhtsian RG, Johnson R, Sumkin J, Dabbs DJ. The clinical significance of lobular neoplasia on breast core biopsy. Am J Surg Pathol. 2007 May;31(5):717-23. | CrossRef | PubMed
36. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008 Mar 10;26(8):1331-7. Epub 2008 Feb 11. | CrossRef | PubMed
37. Khan SA, Wiley EL, Rodriguez N, Baird C, Ramakrishnan R, Nayar R, et al. Ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst. 2004 Oct 20;96(20):1510-7. | CrossRef | PubMed
38. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001 Nov 14;286(18):2251-6. | CrossRef | PubMed
39. Komenaka IK, Ditkoff BA, Joseph KA, Russo D, Gorroochurn P, Ward M, et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer. 2004 May 15;100(10):2079-83. | CrossRef | PubMed
40. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009 Jan 10;27(2):279-88. Epub 2008 Dec 8. | CrossRef | PubMed
41. Liberman L, Sama M, Susnik B, Rosen PP, LaTrenta LR, Morris EA, et al. Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings. AJR Am J Roentgenol. 1999 Aug;173(2):291-9. | PubMed
42. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006 Feb;19(2):264-71. | CrossRef | PubMed
43. Locke I, Mitchell G, Eeles R. Ductal approaches to assessment and management of women at high risk for developing breast cancer. Breast Cancer Res. 2004;6(2):75-81. Epub 2004 Jan 26. | CrossRef | PubMed
44. Longacre TA, Ennis M, Quenneville LA, Bane AL, Bleiweiss IJ, Carter BA, et al. Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol. 2006 Feb;19(2):195-207. | CrossRef | PubMed
45. Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer. 2007 Sep;43(13):1905-17. Epub 2007 Aug 2. | CrossRef | PubMed
46. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med (Berl). 2006 Jan;84(1):16-28. Epub 2005 Nov 11. | PubMed
47. Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer. 2007 Mar 15;109(6):1011-8. | CrossRef | PubMed
48. Mariuzzi L, Mombello A, Granchelli G, Rucco V, Tarocco E, Frank D, et al. Quantitative study of breast cancer progression: different pathways for various in situ cancers. Mod Pathol. 2002 Jan;15(1):18-25. | CrossRef | PubMed
49. Martin RF. Surgical Clinics of North America. Surg Clin N Am 87. 2007.
50. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61. | CrossRef | PubMed
51. McTiernan A. Behavioral risk factors in breast cancer: can risk be modified? Oncologist. 2003;8(4):326-34. | CrossRef | PubMed
52. Middleton LP, Grant S, Stephens T, Stelling CB, Sneige N, Sahin AA. Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised? Mod Pathol. 2003 Feb;16(2):120-9. | CrossRef | PubMed
53. Norum J, Hagen AI, Maehle L, Apold J, Burn J, Møller P. Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis. Eur J Cancer. 2008 May;44(7):963-71. Epub 2008 Mar 24. | CrossRef | PubMed
54. O'Driscoll D, Warren R, MacKay J, Britton P, Day NE. Screening with breast ultrasound in a population at moderate risk due to family history. J Med Screen. 2001;8(2):106-9. | CrossRef | PubMed
55. Oratz R, Paul D, Cohn AL, Sedlacek SM. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract. 2007 Jul;3(4):182-6. | CrossRef | PubMed
56. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004 Dec 30;351(27):2817-26. Epub 2004 Dec 10. | CrossRef | PubMed
57. Peralta O, Reyes JM. Quimioprevención en cáncer de mama. Rev. Med. Clin. Condes - 2006; 17(4): 186 – 93. | Link
58. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747-52. | CrossRef | PubMed
59. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006 May 24;295(20):2374-84. | CrossRef | PubMed
60. Rock CL, Demark-Wahnefried W. Can lifestyle modification increase survival in women diagnosed with breast cancer? J Nutr. 2002 Nov;132(11 Suppl):3504S-3507S. | PubMed
61. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobágyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008 May;13(5):477-93. | CrossRef | PubMed
62. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89. | CrossRef | PubMed
63. Schrading S, Kuhl CK. Mammographic, US, and MR imaging phenotypes of familial breast cancer. Radiology. 2008 Jan;246(1):58-70. | PubMed
64. Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, et al. Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer. 2008 Nov 15;113(10):2627-37. | CrossRef | PubMed
65. Shin SJ, Rosen PP. Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy. Arch Pathol Lab Med. 2002 Jun;126(6):697-701. | PubMed
66. Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, et al. Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. European Commission Working Group on Breast Screening Pathology. Hum Pathol. 1998 Oct;29(10):1056-62. | PubMed
67. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. | CrossRef | PubMed
68. Suzuki R, Ye W, Rylander-Rudqvist T, Saji S, Colditz GA, Wolk A. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst. 2005 Nov 2;97(21):1601-8. | CrossRef | PubMed
69. Veltman J, Mann R, Kok T, Obdeijn IM, Hoogerbrugge N, Blickman JG, et al. Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI. Eur Radiol. 2008 May;18(5):931-8. Epub 2008 Feb 13. | CrossRef | PubMed
70. Vogel VG. Management of the high-risk patient. Surg Clin North Am. 2003 Aug;83(4):733-51. | CrossRef | PubMed
71. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. | CrossRef | PubMed
72. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med. 2008 May 6;148(9):671-9. | PubMed
73. Worsham MJ, Abrams J, Raju U, Kapke A, Lu M, Cheng J, et al. Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population. Breast J. 2007 Mar-Apr;13(2):115-21. | CrossRef | PubMed
74. Zagouri F, Sergentanis TN, Zografos GC. Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol. 2007 May 31;5:57. | CrossRef | PubMed
75. Zakaria S, Degnim AC. Prophylactic mastectomy. Surg Clin North Am. 2007 Apr;87(2):317-31, viii. | CrossRef | PubMed
76. Zavagno G, Carcoforo P, Marconato R, Franchini Z, Scalco G, Burelli P, et al. Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. BMC Cancer. 2005 Mar 11;5:28. | CrossRef | PubMed